Chemistry:RG-7351

From HandWiki

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed by Hoffmann-La Roche.[1][2][4]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "RG 7351". AdisInsight. Springer Nature Switzerland AG. 5 November 2023. https://adisinsight.springer.com/drugs/800031597. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on RG-7351 with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/aa992ac0fafe4f1f910bfb5ec30ec234. 
  3. ↑ "TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg". Frontiers in Pharmacology 9: 279. 2018. doi:10.3389/fphar.2018.00279. PMID 29636691. 
  4. ↑ 4.0 4.1 4.2 "Trace amine-associated receptor 1 and drug abuse". Behavioral Pharmacology of Drug Abuse: Current Status. Adv Pharmacol. 93. 2022. pp. 373–401. doi:10.1016/bs.apha.2021.10.005. ISBN 978-0-323-91526-7. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:RG-7351&oldid=4031906"